This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Redfern CH , Guthrie TH , Bessudo A , Densmore JJ , Holman PR , Janakiraman N , Leonard JP , Levy RL , Just RG , Smith MR , Rosenfelt FP , Wiernik PH , Carter WD , Gold DP , Melink TJ , Gutheil JC , Bender JF
Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses
J Clin Oncol. 2006 Jul 1;24(19) :3107-12
PMID: 16754937 URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16754937
AbstractPURPOSE: To evaluate idiotype (Id) vaccination as a single agent in previously treated patients with indolent non-Hodgkin's lymphoma. PATIENTS AND METHODS: Patients underwent biopsy for determination of their lymphoma-specific Id sequence. Recombinant Id protein was manufactured and covalently linked with keyhole limpet hemocyanin (KLH) to generate Id/KLH. Patients received Id/KLH 1 mg on day 1 subcutaneously, with granulocyte-macrophage colony-stimulating factor 250 mug on days 1 to 4, monthly for 6 months. Booster injections were administered until progression. Both clinical and immune responses were evaluated. RESULTS: Thirty-two previously treated patients received at least one injection of Id/KLH, and 31 were assessed for efficacy. Responses were observed in four patients (one complete response and three partial responses). Median time to onset of response was 5.9 months (range, 2.3 to 14.1 months). Median duration of response has not been reached but should be at least 19.4 months (range, 10.4 to 27.2+ months). Median time to progression is 13.5 months. The most common adverse events were mild to moderate injection site reactions. Six (67%) of nine patients tested demonstrated a cellular immune response, and four (20%) of 20 patients demonstrated an antibody response against their Id. CONCLUSION: This trial demonstrates that Id/KLH alone can induce tumor regression and durable objective responses. Further study of Id/KLH is recommended in other settings where efficacy may be further enhanced as in first-line therapy or after cytoreductive therapy.
NotesRedfern, Charles H Guthrie, Troy H Bessudo, Alberto Densmore, John J Holman, Peter R Janakiraman, Nalini Leonard, John P Levy, Richard L Just, Richard G Smith, Mitchell R Rosenfelt, Fred P Wiernik, Peter H Carter, William D Gold, Daniel P Melink, Teresa J Gutheil, John C Bender, John F Clinical Trial, Phase II Multicenter Study United States Journal of clinical oncology : official journal of the American Society of Clinical Oncology J Clin Oncol. 2006 Jul 1;24(19):3107-12. Epub 2006 Jun 5.